Skip to main content

The prognostic significance of PD-L1 and PD-1 expression in patients with nasopharyngeal carcinoma: a systematic review and meta-analysis



Whether PD-L1/PD-1 expression plays a significant role in the prognosis of NPC is still controversial. The present study mainly aimed to investigate the prognostic significance of PD-L1/PD-1 expression in patients with NPC.


A systematical research was performed in the PubMed, Web of Science, EMBASE, and the Cochrane Library databases up to January 06, 2019. Eighteen studies met eligible criteria were included in the meta-analysis. Quality assessment of included articles was evaluated by Newcastle–Ottawa quality assessment scale (NOS). Pooled hazard ratios (HRs) and their corresponding 95% confidence intervals (95% CIs) were used to elucidated the primary endpoint, overall survival (OS), and the secondary endpoints. Furthermore, the relationship between clinicopathological features of NPC and PD-L1/PD-1 expression was estimated by relative ratios (RRs) and 95% CIs.


A total of 1836 patients from 15 included studies concerning PD-L1 and 678 patients from six studies regarding PD-1 were included in the meta-analysis. Pooled results revealed that PD-L1 expression in NPC did not correlate with OS (HR 1.34 95% CI 0.93–1.93, p = 0.11), DFS (HR 1.82, 95% CI 0.86–3.85, p = 0.12), PFS (HR 1.19, 95% CI 0.46–3.08, p = 0.72), and DMFS (HR 2.26, 95% CI 0.60–8.56, p = 0.23). Meanwhile, no statistically significant differences existed between the expression level of PD-1 in tumor infiltrating lymphocytes (TILs) and the OS in NPC, with the pooled HR 1.29 (95% CI 0.68–2.42, p = 0.44). In subgroup analysis, higher expression of PD-L1 in immune cells correlated with better OS in patients with NPC, with a pooled HR 0.68 (95% CI 0.47–0.99, p = 0.04). Among the clinicopathological features included in our study, we found that the positive expression of PD-L1 in NPC associated with the higher expression of PD-1 (RR 1.25, 95% CI 1.02–1.52, p = 0.03).


Our meta-analysis indicated that higher/positive expression of PD-L1/PD-1 may not serve as suitable biomarkers for the prognosis of NPC, which was not in consistent with some previous studies about the prognostic value of PD-L1/PD-1 in other types of tumors. Despite the positive results in subgroup analysis and study about clinicopathological features, it may still need corroboration of prospective and large-scale studies.


Nasopharyngeal carcinoma (NPC) is a malignancy with remarkable difference in region distributions, which is of high incidence in the Southeast Asia, the Arctic region, and the North Africa, especially in the Guangdong Province in Southern China [1]. In accordance with the coming era of intensity-modulated radiation therapy (IMRT) and increasing applications of potent chemotherapy, the overall survival and tumor local control rate of patients with nasopharyngeal carcinoma have been considerably improved [2, 3]. Despite the best available treatment, local recurrence and distant metastasis remain to be the main reason for failure after NPC treatment, approximately 5–15% and 15–30%, respectively [4]. Recently, increasing numbers of clinical trials concerning immunotherapy have shown promising effects on patients with nasopharyngeal carcinoma [5, 6]. These studies indicate that the mechanisms of immune evasion exert an enormous function on the pathogenesis of NPC. For these reasons, it would be invaluable for optimizing the treatment in NPC patients that if we could elucidate the relationship between the molecules in immune system and NPC.

As is well known, tumor cells can display immune evasion by activating immune checkpoint molecules. Programmed cell death ligand-1 (PD-L1), an immunoinhibitory molecule, has the function of inducing T-cell-mediated immune tolerance, including anergy and apoptosis, by activating programmed cell death-1 (PD-1) located on the surface of T cells [7]. Therefore, immune therapies targeting PD-1/PD-L1 axis have shown significant anti-tumor effect in some types of solid tumors, including melanoma, non-small-cell lung cancer, and head and neck carcinomas [8].

PD-L1 has been proven to be overexpressed in many types of cancer cells and associated with different clinical outcomes, either better or worse, depending on the categories of tumor [9,10,11,12]. Also, there are some controversial about the prognostic value of PD-L1 expression on particular types of cancer, such as breast cancer [13, 14], and nasopharyngeal carcinoma [15,16,17]. However, there is relatively fewer studies towards the prognostic value of PD-1 expression in patients with cancer. A meta-analysis study demonstrated that the positive expression of PD-1 in TILs correlated with poorer overall survival in patients with epithelial-originated cancer, while the study did not include any data about nasopharyngeal carcinoma [18].

Since the prognostic value of PD-L1 or PD-1 expression in nasopharyngeal carcinoma remains unclear, the aim of the present study was to incorporate all available data using the method of meta-analysis to explore whether different expression status of PD-L1 or PD-1 in patients suffering for nasopharyngeal carcinoma have an effect on their survivals. Also, the correlation between clinicopathological features in patients with NPC and PD-1/PD-L1 expression has been evaluated.


Protocol and registration

This systematic review has been conducted following the “Preferred Reporting Items for Systematic Reviews and Meta-Analyses” (PRISMA) guidelines [19] and the Cochrane Handbook [20]. Also, this review was registered ahead on the online database of International prospective register of systematic reviews (PROSPERO) with the Registration Number of CRD42018109532.

Search strategy

We performed the literature research in the PubMed, Web of Science, EMBASE, and the Cochrane Library databases for all relevant original articles up to January 06, 2019. The comprehensive search strategies were based on the combinations of the following key words: “programmed cell death-ligand 1, PD-L1, CD274, B7-H1, programmed cell death 1, PD-1, CD279” AND “nasopharyngeal, nasopharynx” AND “carcinoma, tumor, cancer”, with language restricted in English. In addition to the search online, manual search was performed on the reference lists of retrieved articles as well to broaden the search. When it occurs that multiple articles include the same cohort of NPC patients, multiple aspect of evaluation would be carried out in order to decide the final included report.

Inclusion and exclusion criteria

The eligible criteria were the following: cohort studies were conducted in human with NPC and the diagnosis of NPC was confirmed by pathology; the expression status of PD-1 or PD-L1 was detected: the correlation between PD-1/PD-L1 and overall survival (OS), disease-free survival (DFS), progression-free survival (PFS), or distant-metastasis free survival (DMFS) were elucidated by hazard ratio (HR) and its 95% confidence intervals (95% CI) or Kaplan–Meier curve [21]. Studies were excluded if they met either of the following exclusion criteria: review or basic research; conference abstract or letters; as well as case report or clinical trials.

Data extraction and quality assessment

Two investigators (Zi-Lu Huang and Shan Liu) independently extracted relevant data from the included studies and summarized it. Any disagreements appeared would be resolved by consulting an adjudicating senior author (YF Xia). The following data were extracted from the eligible studies: name of the first author, year of publication, country where the study was carried out, number of patients, clinicopathological features in different expression of PD-1/PD-L1, cut off value for PD-1/PD-L1 overexpression, detection area, detection methods, prognostic endpoints of interest, statistical analysis approach, and HR and its 95% CI for the endpoints of interest.

The methodological quality of the retrieved articles was evaluated according to the Newcastle–Ottawa quality assessment scale (NOS) for cohort study. The scale is composed of eight items of assessment that can be divided into the following three subgroups: selection, comparability, and outcome, with the subtotal score of 4, 2, and 3, respectively. Finally, a total score of 0–9 was distributed to each eligible study.

Endpoints of interest and statistical analysis

The primary endpoint of our study was overall survival (OS). If adequate data is available, the primary outcomes would be subdivided in order to make further analysis of subgroups. The secondary endpoints were disease-free survival (DFS), progression-free survival (PFS), distant-metastasis free survival (DMFS), and the clinicopathological factors.

The statistical analysis was performed using Review Manager 5.3 (Cochrane Collaboration, Oxford, UK) and STATA 14. We estimated the prognostic significance of PD-1/PD-L1 expression in NPC by directly using HR and its 95% CI when the original articles reported, otherwise, the Kaplan–Meier curve would be used to obtain HR and its 95% CI using the method provided by Tierney et al. [21]. Statistical heterogeneity between studies was quantified by using the Q test and the I2 statistic. The p-value of Q test lower than 0.1 or the statistic of I2 higher than 50% was considered that it existed heterogeneity between studies. When it appeared heterogeneity, a random effects model would be chosen to pool the data, otherwise, a fixed effects model would be used. Subgroup analysis and sensitivity analysis were performed to track the origin of the heterogeneity. In this article, we adopted HR > 1 as the benchmark of PD-1/PD-L1 overexpression indicating a poorer outcome. We evaluated the publication bias through the Begg’s and Egger’s test in quantitatively. A two-tailed p value < 0.05 was considered to be statistically significant.


Study selection

A total of 330 articles were obtained through the search strategy mentioned above. After removing duplicates, a number of 229 studies left. We performed a screening of title and abstract on the 229 records and 208 records were excluded according to the inclusion and exclusion criterion. The remaining 21 studies were included in the full-text evaluation. Among these, 2 articles didn’t provide available survival data and 1 article was found not written in English. Finally, 18 articles were included in our meta-analysis, including 15 for PD-L1 and 6 for PD-1, severally. There were three studies that not only supplied available data for PD-L1 but also for PD-1. The selection flowchart was displayed in Fig. 1.

Fig. 1

Selection flowchart of the included studies

Study characteristics

A total of 1836 patients from 15 included studies concerning PD-L1 [15,16,17, 22,23,24,25,26,27,28,29,30,31,32,33] and 678 patients from six studies regarding PD-1 [22, 30, 31, 34,35,36] were included in the meta-analysis. The publication year of PD-L1 and PD-1 ranged from 2014 to 2018 and 2010 to 2018, respectively. All the included studies were performed in Asia and the majority of these studies were carried out in China. The primary endpoint, OS, was discussed among 11 studies in PD-L1 and six studies in PD-1. The included studies vary in their detection regions of PD-L1/PD-1 expression and the cut-off value for PD-L1/PD-1 positive, which may consequently have an effect on the positive rate of PD-L1/PD-1 overexpression. The quality score differs from 6 to 9 on the basis of the Newcastle–Ottawa quality assessment scale (NOS). The baseline characteristics of included studies are listed in Tables 1 and 2, separately for PD-L1 and PD-1. Among those studies none was found utilized the same cohort of patients.

Table 1 Main characteristics of included studies about PD-L1 in this meta-analysis
Table 2 Main characteristics of included studies about PD-1 in this meta-analysis

Synthesis of results

As depicted in Fig. 2, pooling the data from 12 studies that assessed the prognostic value of PD-L1 expression in NPC showed no significant association between PD-L1 expression and OS, with the pooled HR 1.34 (95% CI 0.93–1.93, p = 0.11). Furthermore, a random-effects model was adopted for the reason that a significant heterogeneity was calculated among the studies (I2 = 75%, p < 0.000). For the secondary endpoints, no significant correlation was observed between the expression of PD-L1 and DFS (HR 1.82, 95% CI 0.86–3.85, p = 0.12), PFS (HR 1.19, 95% CI 0.46–3.08, p = 0.72), and DMFS (HR 2.26, 95% CI 0.60–8.56, p = 0.23) likewise (Figs. 3, 4 and 5). It was demonstrated in Fig. 6 that no statistically significant differences existed between the expression level of PD-1 in tumor infiltrating lymphocytes and the OS in NPC, with the pooled HR 1.29 (95% CI 0.68–2.42, p = 0.44). Meta-analysis concerning the prognostic value of PD-1 in NPC was not performed in the secondary endpoints, DFS and PFS, due to the lack of adequate studies.

Fig. 2

Forest plot for overall survival (OS) of PD-L1 high expression in nasopharyngeal carcinoma

Fig. 3

Forest plot for disease-free survival (DFS) of PD-L1 high expression in nasopharyngeal carcinoma

Fig. 4

Forest plot for progression-free survival (PFS) of PD-L1 high expression in nasopharyngeal carcinoma

Fig. 5

Forest plot for distant-metastasis free survival (DMFS) of PD-L1 high expression in nasopharyngeal carcinoma

Fig. 6

Forest plot for overall survival (OS) of PD-1 high expression in nasopharyngeal carcinoma

Sensitivity analysis and subgroup analysis

The results of sensitivity analysis and subgroup analysis on the correlation of PD-L1 expression and OS in NPC were displayed on Table 3. Sensitivity analysis was performed and we found the most significant heterogeneity originated from the study of Li et al. [26]. After remove it, I2 decreased to 40% and p value of heterogeneity increased to 0.08, with the pooled HR 1.07 and its 95% CI 0.84–1.36. Subgroup analysis was carried out on the cut-off value of PD-L1 positive, and the results indicated that no significant correlation existed between the cut-off value for PD-L1 positive (both ≥ 5% and ≥ 1%) and OS in NPC patients. It was noteworthy that heterogeneity was not as remarkable as the pooled data before, when we conducted the subgroup analysis based on the cut-off value for PD-L1 positive. (I2 = 0% and p = 0.77, I2 = 0% and p = 0.59, particularly.) Subgroup analysis was also performed on the basis of detection area. Compared with higher expression of PD-L1 in tumor cells, an advantage of overall survival was shown in the set of PD-L1 lower expression. However, the difference was not statistically significant (HR 1.55, 95% CI 0.99–2.42, p = 0.06). A statistical difference was observed between the PD-L1 expression in immune cells and OS in patients of NPC, with a pooled HR 0.68 (95% CI 0.47–0.99, p = 0.04) and a fixed-effects model was used. We found no significant difference in subgroup analysis of the estimation and calculation methods of HRs.

Table 3 Subgroup analysis of included studies about PD-L1 and OS in this meta-analysis

Clinicopathological features

The relationship between clinicopathological factors and the expression level of PD-L1/PD-1 in NPCs was summarized in Table 4a and b. The features included in this article were mainly as follows: gender, TNM stage, tobacco or alcohol use, Epstein–Barr virus (EBV) status, pathologic types. Among these characteristics, no statistical difference was discovered. However, we found that the positive expression of PD-L1 in NPCs correlated with the higher expression of PD-1 (RR 1.25, 95% CI 1.02–1.52, p = 0.03).

Table 4 The relationship between clinicopathological factors and the expression level of (a) PD-L1 in NPCs, (b) PD-1 in NPCs

Publication bias

In our meta-analysis, the publication bias was assessed by Begg’s funnel plot and Egger’s test. 12 articles concerning the impact of PD-L1 expression on OS in patients of NPC was included in these two tests. No evidence observed in Begg’s funnel plot (p = 0.273) (Fig. 7, Additional file 1) and Egger’s test (p = 0.224) (Fig. 8, Additional file 1) showed publication bias among these studies.

Fig. 7

Begg’s funnel plot for assessing publication bias for the impact of PD-L1 expression on OS in patients of nasopharyngeal carcinoma

Fig. 8

Egger’s plot for assessing publication bias for the impact of PD-L1 expression on OS in patients of nasopharyngeal carcinoma


This meta-analysis of 18 retrospective cohort studies including 15 articles covering PD-L1 and six studies concerning PD-1, a total of 1836 patients, comparing different expression level of PD-L1/PD-1 and the prognosis of NPC showed that no statistical significance was found between higher/positive expression of PD-L1/PD-1 and the prognosis of NPC. Among the subgroup analysis, when the detection area of PD-L1 was the immune cells, a higher expression of PD-L1 displayed better overall survival in NPC. Observing all the clinicopathological characteristics, only the expression of PD-L1 was found correlate with PD-1, and no other clinicopathological features was related with the expression of PD-L1/PD-1.

PD-1, known as an inhibitory receptor, which is mainly expressed on activated T lymphocytes, but also can be observed on B cells and NK cells [37]. PD-L1 as well as PD-L2, one of the ligands for PD-1 receptor, belonging to B7 family is found expressed on PD-L1 contributes to the tolerance and impairment of the immune system [38]. The tumor microenvironment makes contribution to the upregulation of PD-1 expression in TILs, which leads to the impairment of antitumor immune. Since the upregulated PD-1 in TILs will result in an exhausted phenotype and impaired function of T cells in TILs [39]. At the same time, it is known that PD-L1 has been discovered expressing on many types of tumor lines, and its combination with PD-1 in TILs serves as one of the pivotal mechanism of modulating tumor cells with immunogenicity to escape from the surveillance of the host immune system [40].

On account of various of tumor types and therapeutics, the prognostic value of PD-L1/PD-1 in tumor has not reach a consensus. In a meta-analysis about solid tumors included 61 articles showed that the overexpression of PD-L1 suggested a worse prognosis [41]. However, when it comes to some specific types of tumors, the results were not the same. For instance, a study pooled 11 articles revealed that the expression of PD-L1 had no statistical correlation with the prognosis of patients with oral squamous cell carcinoma, whatever in OS, DFS or disease-specific survival (DSS) [42]. In addition, another meta-analysis concerning osteosarcoma involving eight original studies indicated that the overexpression of PD-L1/PD-1 significantly related with a higher incidence of metastasis and total mortality risk [43].

In our study, the prognostic value of PD-L1 expression in NPC was reported in 15 eligible studies. A previous study regarding the correlation of PD-L1 expression and head and neck carcinoma (HNC) included 17 original articles totally, while only 2 of them are about NPC [44]. The conclusions drawn from the present study are something different from the previous one. The meta-analysis study about HNC demonstrated that no association was found between PD-L1 expression and the prognosis of HNC, however, the subgroup analysis indicated that in the group of Asia regions/countries a poorer OS in HNC may correlated with positive expression of PD-L1. Compared with the previous study, original studies included in our meta-analysis were all done in Asia regions/countries and the pooled data revealed no statistical difference between the expression level of PD-L1 and prognosis of NPC. It may be because nasopharyngeal carcinoma and non-nasopharyngeal head and neck cancer vary in their clinicopathological features and therapeutics.

The results of another recently published meta-analysis elucidating the prognostic value of some immune checkpoints in head and neck cancer were completely different from our meta-analysis and the previous study of head and neck that we just mentioned above [45]. The analysis demonstrated that PD-L1 expression higher indicated better OS in HNC, especially in NPC (p = 0.01). While, by comparison with our study, several obvious distinctions deserve to be concerned. First, we found that it only included seven studies in the meta-analysis of PD-L1 expression in NPC about OS, by contrast, the present study included 12 eligible studies to pool the data regarding the impact of PD-L1 expression in OS, containing the previous seven studies. Second, some details of the data (HR and 95% CI) adopted were nuance. Since a few of survival data were derived from Kaplan–Meier curve, data deviation was inevitable. Also, when the eligible original articles provided two or more alternative survival data, choice among researchers could not reach unanimous unless prior discussion. For example, the study of Ono et al. [27] offered the results of both univariate and multivariate, however, Jia et al. [45] utilized the univariate one and our meta-analysis chose multivariate one. Similarly, Chang et al. [23] supplied survival data in accordance with two PD-L1 cut-off value, while Jia et al. [45] used the 1% cut-off value and we adopted the most common one, 5% cut-off value, to pool data.

Among all the original reports eligible in our study, some of the studies demonstrated that relatively higher expression of PD-L1 or PD-1 in NPC predicts worse prognosis [22, 24, 26, 28, 29, 31, 34,35,36]. The most common and convincing explanation for the result was the interactions of PD-1 and PD-L1 would lead to immune suppression and promote tumor progression [38, 40]. None of the multivariate analysis results in eligible studies approved for the main conclusion drew in Jia et al. [45]. Remaining original studies declared no statistically significant difference in the expression of PD-1 or PD-L1 and the prognosis of NPC, which were consistent with our conclusion.

Interferon-gamma (IFN-γ) has been shown to be detected in tumor cells with PD-L1 positive and TILs, and act as a primary inducer for PD-L1 expression, while it could not be detected in PD-L1 negative tumor cells [46]. Therefore, PD- L1 expression may not directly result in immune evasion and it may represent an outcome of on-going immune system triggers immune inhibition by producing IFN-γ or other cytokines [25, 46]. In the tumor microenvironment of NPC, the condition of infiltrating lymphocytes is more complexity, on account of the high infectious rate of Epstein–Barr virus (EBV) in NPC [47]. Sustainably exposure in viral contributes to more active inflammatory reactions resulting in the expression of PD-L1 [48, 49]. It can be inferred that the expression of PD-L1 in NPC may just reflect the inflammatory response in the tumor microenvironment, which may need further research to identify. The expression of PD-1 in TILs have been shown to be dynamically changed in conformity to the status of immune system and tumor microenvironment, which may illustrate the undefinition of the prognostic value of PD-1 expression in NPC [30, 50]. Recently, more and more clinical trials are focusing on immunotherapy in HNC, especially anti-PD-L1/PD-1 antibody in NPC. Hsu et al. [5] reported a phase Ib clinical trial about anti-PD-1 monoclonal antibody, pembrolizumab, in NPC with PD-L1 positive, and revealed its antitumor activity and manageable adverse events. Another phase I trials concerning anti-PD-1 antibody, camrelizumab, in NPC also derives positive results [51]. Colevas et al. [52] conducted phase Ia trials regarding anti-PD-L1, atezolizumab, in HNC, and get encouraging antitumor activity regardless of PD-L1 expression. Since increasing researchers are concerning about the immunotherapy of anti-PD-L1/PD-1 antibody in NPC, it is worthwhile to figure out the role of PD-L1/PD-1 plays in the tumor microenvironment and prognosis of NPC.

Our meta-analysis performed sensitivity analysis on the outcome of OS regarding PD-L1 by cut-off value, detection area, calculation of HRs, and estimation method of HRs. Though we found that higher expression of PD-L1 in immune cells correlated with better OS, it only included three studies evoking the conclusion may not be robust. When we exclude the study of Li et al. [26], heterogeneity decreased most obviously compared with deleting other single studies. We speculated that it may because of its unique cut-off value for PD-L1 and the estimation of HR was based on Kaplan–Meier curve. Furthermore, we discovered that its quality score was the lowest. However, excluding the study did not influence the main conclusion we drew. We failed to perform subgroup analysis among studies about PD-1, due to the deficiency of related original studies, which is a limitation of our study. Another limitation in our analysis is that the heterogeneity is obvious among studies, and it may originate from varied cut-off value for PD-L1 positive based on the subgroup analysis and summarization of main characteristics of eligible studies. The cut-off value for PD-L1/PD-1 positive in tumor microenvironment may need further discussion to determine suitable world-wide criterions in accordance with different types of tumors.


Our study revealed that the expression level of PD-L1 or PD-1 may not act as a useful predict biomarkers for the prognosis of NPC. The positive results obtained in subgroup analysis and clinicopathological analysis need further studies to be confirmed.

Availability of data and materials

The databases analyzed during the current study are available.



confidence interval


disease-free survival


distant metastasis-free survival


Epstein–Barr virus


Formalin-Fixed and Paraffin-Embedded


hazard ratios


immune cells





K–M curve:

Kaplan–Meier curve


not available




Newcastle–Ottawa quality assessment scale


nasopharyngeal carcinoma


overall survival


programmed cell death-1


programmed cell death ligand-1


progression-free survival


tumor cells


tumor-infiltrating lymphocytes


  1. 1.

    Yu MC, Yuan JM. Epidemiology of nasopharyngeal carcinoma. Semin Cancer Biol. 2002;12(6):421–9.

    Article  Google Scholar 

  2. 2.

    Lee AW, Ng WT, Chan LL, Hung WM, Chan CC, Sze HC, et al. Evolution of treatment for nasopharyngeal cancer—success and setback in the intensity-modulated radiotherapy era. Radiother Oncol. 2014;110(3):377–84.

    Article  Google Scholar 

  3. 3.

    Zhang B, Mo Z, Du W, Wang Y, Liu L, Wei Y. Intensity-modulated radiation therapy versus 2D-RT or 3D-CRT for the treatment of nasopharyngeal carcinoma: a systematic review and meta-analysis. Oral Oncol. 2015;51(11):1041–6.

    Article  Google Scholar 

  4. 4.

    Lee AW, Ma BB, Ng WT, Chan AT. Management of nasopharyngeal carcinoma: current practice and future perspective. J Clin Oncol. 2015;33(29):3356–64.

    Article  Google Scholar 

  5. 5.

    Hsu C, Lee SH, Ejadi S, Even C, Cohen RB, Le Tourneau C, et al. Safety and antitumor activity of pembrolizumab in patients with programmed death-ligand 1-positive nasopharyngeal carcinoma: results of the KEYNOTE-028 Study. J Clin Oncol. 2017;35(36):4050–6.

    CAS  Article  Google Scholar 

  6. 6.

    Ma BBY, Lim WT, Goh BC, Hui EP, Lo KW, Pettinger A, et al. Antitumor activity of nivolumab in recurrent and metastatic nasopharyngeal carcinoma: an international, multicenter study of the mayo clinic phase 2 consortium (NCI-9742). J Clin Oncol. 2018;36(14):1412–8.

    CAS  Article  Google Scholar 

  7. 7.

    Okazaki T, Honjo T. PD-1 and PD-1 ligands: from discovery to clinical application. Int Immunol. 2007;19(7):813–24.

    CAS  Article  Google Scholar 

  8. 8.

    Chen L, Han X. Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future. J Clin Invest. 2015;125(9):3384–91.

    Article  Google Scholar 

  9. 9.

    Wang X, Teng F, Kong L, Yu J. PD-L1 expression in human cancers and its association with clinical outcomes. OncoTargets Ther. 2016;9:5023–39.

    CAS  Article  Google Scholar 

  10. 10.

    Ohigashi Y, Sho M, Yamada Y, Tsurui Y, Hamada K, Ikeda N, et al. Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer. Clin Cancer Res. 2005;11(8):2947–53.

    CAS  Article  Google Scholar 

  11. 11.

    Wu C, Zhu Y, Jiang J, Zhao J, Zhang XG, Xu N. Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance. Acta Histochem. 2006;108(1):19–24.

    Article  Google Scholar 

  12. 12.

    Lipson EJ, Vincent JG, Loyo M, Kagohara LT, Luber BS, Wang H, et al. PD-L1 expression in the Merkel cell carcinoma microenvironment: association with inflammation, Merkel cell polyomavirus and overall survival. Cancer Immunol Res. 2013;1(1):54–63.

    CAS  Article  Google Scholar 

  13. 13.

    Ghebeh H, Mohammed S, Al-Omair A, Qattan A, Lehe C, Al-Qudaihi G, et al. The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors. Neoplasia. 2006;8(3):190–8.

    CAS  Article  Google Scholar 

  14. 14.

    Schalper KA, Velcheti V, Carvajal D, Wimberly H, Brown J, Pusztai L, et al. In situ tumor PD-L1 mRNA expression is associated with increased TILs and better outcome in breast carcinomas. Clin Cancer Res. 2014;20(10):2773–82.

    CAS  Article  Google Scholar 

  15. 15.

    Zhang J, Fang W, Qin T, Yang Y, Hong S, Liang W, et al. Co-expression of PD-1 and PD-L1 predicts poor outcome in nasopharyngeal carcinoma. Med Oncol. 2015;32(3):86.

    Article  Google Scholar 

  16. 16.

    Zhu Q, Cai MY, Chen CL, Hu H, Lin HX, Li M, et al. Tumor cells PD-L1 expression as a favorable prognosis factor in nasopharyngeal carcinoma patients with pre-existing intratumor-infiltrating lymphocytes. Oncoimmunology. 2017;6(5):e1312240.

    Article  Google Scholar 

  17. 17.

    Chan OS, Kowanetz M, Ng WT, Koeppen H, Chan LK, Yeung RM, et al. Characterization of PD-L1 expression and immune cell infiltration in nasopharyngeal cancer. Oral Oncol. 2017;67:52–60.

    CAS  Article  Google Scholar 

  18. 18.

    Zhang Y, Kang S, Shen J, He J, Jiang L, Wang W, et al. Prognostic significance of programmed cell death 1 (PD-1) or PD-1 ligand 1 (PD-L1) Expression in epithelial-originated cancer: a meta-analysis. Medicine. 2015;94(6):e515.

    CAS  Article  Google Scholar 

  19. 19.

    Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol. 2009;62(10):e1–34.

    Article  Google Scholar 

  20. 20.

    Higgins JPT GSe. Cochrane handbook for systematic reviews of interventions Version 5.1.0. The Cochrane Collaboration. 2011. Updated March 2011.

  21. 21.

    Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;8:16.

    Article  Google Scholar 

  22. 22.

    Cao C, Wei Q, Tang X, Jia Y, Sun X, Li W, et al. PD-1 and PD-L1 in locoregionally advanced nasopharyngeal carcinoma: a substudy of a randomized phase III trial. Head Neck. 2018.

    Article  PubMed  Google Scholar 

  23. 23.

    Chang AMV, Chiosea SI, Altman A, Pagdanganan HA, Ma C. Programmed death-ligand 1 expression, microsatellite instability, Epstein–Barr virus, and human papillomavirus in nasopharyngeal carcinomas of patients from the philippines. Head Neck Pathol. 2017;11(2):203–11.

    Article  Google Scholar 

  24. 24.

    Fang W, Zhang J, Hong S, Zhan J, Chen N, Qin T, et al. EBV-driven LMP1 and IFN-gamma up-regulate PD-L1 in nasopharyngeal carcinoma: implications for oncotargeted therapy. Oncotarget. 2014;5(23):12189–202.

    Article  Google Scholar 

  25. 25.

    Lee VH, Lo AW, Leung CY, Shek WH, Kwong DL, Lam KO, et al. Correlation of PD-L1 expression of tumor cells with survival outcomes after radical intensity-modulated radiation therapy for non-metastatic nasopharyngeal carcinoma. PLoS ONE. 2016;11(6):e0157969.

    Article  Google Scholar 

  26. 26.

    Li YF, Ding JW, Liao LM, Zhang ZL, Liao SS, Wu Y, et al. Expression of programmed death ligand-1 predicts poor outcome in nasopharyngeal carcinoma. Mol Clin Oncol. 2017;7(3):378–82.

    CAS  Article  Google Scholar 

  27. 27.

    Ono T, Azuma K, Kawahara A, Sasada T, Matsuo N, Kakuma T, et al. Prognostic stratification of patients with nasopharyngeal carcinoma based on tumor immune microenvironment. Head Neck. 2018;40(9):2007–19.

    Article  Google Scholar 

  28. 28.

    Qu Y, Wang D, Yang L, Liu HY, Cui W, Che YQ. Expression and clinical significance of programmed death ligand 1 in nasopharyngeal carcinoma. Mol Clin Oncol. 2018;9(1):75–81.

    PubMed  PubMed Central  Google Scholar 

  29. 29.

    Zheng L, Cao C, Cheng G, Hu Q, Chen X. Cytomembranic PD-L1 expression in locoregionally advanced nasopharyngeal carcinoma. OncoTargets Ther. 2017;10:5483–7.

    Article  Google Scholar 

  30. 30.

    Zhou Y, Miao J, Wu H, Tang H, Kuang J, Zhou X, et al. PD-1 and PD-L1 expression in 132 recurrent nasopharyngeal carcinoma: the correlation with anemia and outcomes. Oncotarget. 2017;8(31):51210–23.

    PubMed  PubMed Central  Google Scholar 

  31. 31.

    Zhou Y, Shi D, Miao J, Wu H, Chen J, Zhou X, et al. PD-L1 predicts poor prognosis for nasopharyngeal carcinoma irrespective of PD-1 and EBV-DNA load. Sci Rep. 2017;7:43627.

    Article  Google Scholar 

  32. 32.

    Larbcharoensub N, Mahaprom K, Jiarpinitnun C, Trachu N, Tubthong N, Pattaranutaporn P, et al. Characterization of PD-L1 and PD-1 expression and CD8+ tumor-infiltrating lymphocyte in Epstein–Barr virus-associated nasopharyngeal carcinoma. Am J Clin Oncol. 2018;41(12):1204–10.

    CAS  Article  Google Scholar 

  33. 33.

    Liu YJ, Tsang NM, Hsueh C, Yeh CJ, Ueng SH, Wang TH, et al. Low PD-L1 expression strongly correlates with local recurrence in Epstein–Barr virus-positive nasopharyngeal carcinoma after radiation-based therapy. Cancers. 2018;10(10):374.

    Article  Google Scholar 

  34. 34.

    Hsu MC, Hsiao JR, Chang KC, Wu YH, Su IJ, Jin YT, et al. Increase of programmed death-1-expressing intratumoral CD8 T cells predicts a poor prognosis for nasopharyngeal carcinoma. Mod Pathol. 2010;23(10):1393–403.

    CAS  Article  Google Scholar 

  35. 35.

    Lu J, Chen XM, Huang HR, Zhao FP, Wang F, Liu X, et al. Detailed analysis of inflammatory cell infiltration and the prognostic impact on nasopharyngeal carcinoma. Head Neck. 2018;40(6):1245–53.

    Article  Google Scholar 

  36. 36.

    Tang Y, He Y, Shi L, Yang L, Wang J, Lian Y, et al. Co-expression of AFAP1-AS1 and PD-1 predicts poor prognosis in nasopharyngeal carcinoma. Oncotarget. 2017;8(24):39001–11.

    PubMed  PubMed Central  Google Scholar 

  37. 37.

    Larsson M, Shankar EM, Che KF, Saeidi A, Ellegard R, Barathan M, et al. Molecular signatures of T-cell inhibition in HIV-1 infection. Retrovirology. 2013;10:31.

    CAS  Article  Google Scholar 

  38. 38.

    Keir ME, Liang SC, Guleria I, Latchman YE, Qipo A, Albacker LA, et al. Tissue expression of PD-L1 mediates peripheral T cell tolerance. J Exp Med. 2006;203(4):883–95.

    CAS  Article  Google Scholar 

  39. 39.

    Ahmadzadeh M, Johnson LA, Heemskerk B, Wunderlich JR, Dudley ME, White DE, et al. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood. 2009;114(8):1537–44.

    CAS  Article  Google Scholar 

  40. 40.

    Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci USA. 2002;99(19):12293–7.

    CAS  Article  Google Scholar 

  41. 41.

    Wang Q, Liu F, Liu L. Prognostic significance of PD-L1 in solid tumor: an updated meta-analysis. Medicine. 2017;96(18):e6369.

    CAS  Article  Google Scholar 

  42. 42.

    Troiano G, Caponio VCA, Zhurakivska K, Arena C, Pannone G, Mascitti M, et al. High PD-L1 expression in the tumour cells did not correlate with poor prognosis of patients suffering for oral squamous cells carcinoma: a meta-analysis of the literature. Cell Prolif. 2019;52:e12537.

    Article  Google Scholar 

  43. 43.

    Huang X, Zhang W, Zhang Z, Shi D, Wu F, Zhong B, et al. Prognostic value of programmed cell death 1 ligand-1 (PD-L1) or PD-1 expression in patients with osteosarcoma: a meta-analysis. J Cancer. 2018;9(14):2525–31.

    Article  Google Scholar 

  44. 44.

    Li J, Wang P, Xu YL. Prognostic value of programmed cell death ligand 1 expression in patients with head and neck cancer: a systematic review and meta-analysis. PLoS ONE. 2017;12(6):e0179536.

    Article  Google Scholar 

  45. 45.

    Jia YQ, Yang B, Wen LL, Mu WX, Wang Z, Cheng B. Prognostic value of immune checkpoint molecules in head and neck cancer: a meta-analysis. Aging. 2019;11(2):501–22.

    Article  Google Scholar 

  46. 46.

    Taube JM, Anders RA, Young GD, Xu H, Sharma R, McMiller TL, et al. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med. 2012;4(127):127ra37.

    Article  Google Scholar 

  47. 47.

    Gu AD, Zeng MS, Qian CN. The criteria to confirm the role of Epstein–Barr virus in nasopharyngeal carcinoma initiation. Int J Mol Sci. 2012;13(10):13737–47.

    CAS  Article  Google Scholar 

  48. 48.

    Li Z, Duan Y, Cheng S, Chen Y, Hu Y, Zhang L, et al. EBV-encoded RNA via TLR3 induces inflammation in nasopharyngeal carcinoma. Oncotarget. 2015;6(27):24291–303.

    PubMed  PubMed Central  Google Scholar 

  49. 49.

    Chung YL, Wu ML. Spatiotemporal homogeneity and distinctness of the T-cell receptor beta-chain repertoires in Epstein–Barr virus-associated primary and metastatic nasopharyngeal carcinomas. Int J Cancer. 2018;143(3):610–20.

    CAS  Article  Google Scholar 

  50. 50.

    Odorizzi PM, Pauken KE, Paley MA, Sharpe A, Wherry EJ. Genetic absence of PD-1 promotes accumulation of terminally differentiated exhausted CD8+ T cells. J Exp Med. 2015;212(7):1125–37.

    CAS  Article  Google Scholar 

  51. 51.

    Fang W, Yang Y, Ma Y, Hong S, Lin L, He X, et al. Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials. Lancet Oncol. 2018;19(10):1338–50.

    CAS  Article  Google Scholar 

  52. 52.

    Colevas AD, Bahleda R, Braiteh F, Balmanoukian A, Brana I, Chau NG, et al. Safety and clinical activity of atezolizumab in head and neck cancer: results from a phase I trial. Ann Oncol. 2018;29(11):2247–53.

    CAS  Article  Google Scholar 

Download references


We would like to thank all researchers for their contributions and show our gratitude to Dr. Fan, a respectable, responsible and resourceful scholar, who has provided us with valuable guidance in most stage of writing meta-analysis.


This work was supported by The National Key Research and Development Program of China (No. 2016YFC0902000) and The National Natural Science Funds (Grant No. 81872464).

Author information




Conceptualization: YFX, ZLH, SL. Data analysis: ZLH, SL, GNW, SHZ. Original draft writing: ZLH, SL, SRD, YLT, CC. Review and editing: YFX, ZLH, SL, SRD, XY, HC, XHW. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Yun-Fei Xia.

Ethics declarations

Ethics approval and consent to participate

The present meta-analysis was based on previous published studies, and involved no experiments on humans and animal. Therefore, no ethical approval is required.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Additional file

Additional file 1.

The data of publication bias test.

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (, which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Huang, Z., Liu, S., Wang, G. et al. The prognostic significance of PD-L1 and PD-1 expression in patients with nasopharyngeal carcinoma: a systematic review and meta-analysis. Cancer Cell Int 19, 141 (2019).

Download citation


  • Nasopharyngeal carcinoma
  • PD-L1
  • PD-1
  • Prognostic
  • Meta-analysis